Tags

Type your tag names separated by a space and hit enter

Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
Thromb Res. 2006; 117(5):487-92.TR

Abstract

BACKGROUND

The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer.

MATERIAL AND METHODS

We studied 104 women with breast carcinoma (patient group) and 104 healthy age-matched women (control group). In patients and controls, the PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA.

RESULTS

The frequency of the PAI-1 4G allele tended to be higher in patients than in controls (p=0.062). The presence of the 4G allele (4G/5G plus 4G/4G genotypes) was significantly higher among patients with histological grade 3 tumors than among those with grade 1 tumors (p=0.026). Furthermore, patients with the 4G/4G genotype had significantly higher tissue PAI-1 levels than those with the 5G/5G genotype. Moreover, tissue PAI-1 antigen levels were significantly and positively correlated with tumor severity (p=0.003) and tumor size (p=0.009). However, no significant differences in PAI-1 level were observed in relation to menopause, hormone receptor or nodal status.

CONCLUSION

Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer.

Authors+Show Affiliations

Hospital Universitario La Fe, Centro de Investigación. Avda. Campanar 21, 46009 Valencia, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

15907980

Citation

Castelló, Remedios, et al. "Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Breast Cancer Patients and Its Association With Tissue PAI-1 Levels and Tumor Severity." Thrombosis Research, vol. 117, no. 5, 2006, pp. 487-92.
Castelló R, España F, Vázquez C, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thromb Res. 2006;117(5):487-92.
Castelló, R., España, F., Vázquez, C., Fuster, C., Almenar, S. M., Aznar, J., & Estellés, A. (2006). Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thrombosis Research, 117(5), 487-92.
Castelló R, et al. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism in Breast Cancer Patients and Its Association With Tissue PAI-1 Levels and Tumor Severity. Thromb Res. 2006;117(5):487-92. PubMed PMID: 15907980.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. AU - Castelló,Remedios, AU - España,Francisco, AU - Vázquez,Carlos, AU - Fuster,Carlos, AU - Almenar,Sergio M, AU - Aznar,Justo, AU - Estellés,Amparo, PY - 2005/02/21/received PY - 2005/03/21/revised PY - 2005/03/22/accepted PY - 2005/5/24/pubmed PY - 2006/9/20/medline PY - 2005/5/24/entrez SP - 487 EP - 92 JF - Thrombosis research JO - Thromb Res VL - 117 IS - 5 N2 - BACKGROUND: The plasminogen activator inhibitor type 1 (PAI-1) 4G/5G polymorphism may have significance for PAI-1 expression. High levels of PAI-1 in breast cancer patients are associated with a poor prognosis. In this study, we analyzed the influence of the PAI-1 4G/5G polymorphism on tissue PAI-1 levels and its association with tumor severity in women with breast cancer. MATERIAL AND METHODS: We studied 104 women with breast carcinoma (patient group) and 104 healthy age-matched women (control group). In patients and controls, the PAI-1 4G/5G polymorphism was determined by PCR amplification using allele-specific primers. In patients, PAI-1 levels were quantified in breast cancer tissue by using an ELISA. RESULTS: The frequency of the PAI-1 4G allele tended to be higher in patients than in controls (p=0.062). The presence of the 4G allele (4G/5G plus 4G/4G genotypes) was significantly higher among patients with histological grade 3 tumors than among those with grade 1 tumors (p=0.026). Furthermore, patients with the 4G/4G genotype had significantly higher tissue PAI-1 levels than those with the 5G/5G genotype. Moreover, tissue PAI-1 antigen levels were significantly and positively correlated with tumor severity (p=0.003) and tumor size (p=0.009). However, no significant differences in PAI-1 level were observed in relation to menopause, hormone receptor or nodal status. CONCLUSION: Tissue PAI-1 antigen levels and tumor severity seem to be associated with the PAI-1 4G/5G polymorphism. Further studies with a larger number of patients are needed to clarify the influence of this polymorphism in breast cancer. SN - 0049-3848 UR - https://www.unboundmedicine.com/medline/citation/15907980/Plasminogen_activator_inhibitor_1_4G/5G_polymorphism_in_breast_cancer_patients_and_its_association_with_tissue_PAI_1_levels_and_tumor_severity_ DB - PRIME DP - Unbound Medicine ER -